Evidence map›Paper›PMID 40536267›Full record

ArticleThe oncologist2025

REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens.

Jeffrey Zhong, Albert Jang, Bashar Abuqayas, Arnab Basu, David J Benjamin, Vineel Bhatlapenumarthi, Mehmet Asim Bilen, Dhvani Buch, Mark Chang, Erica Chin and 23 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Jeffrey ZhongDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.ORCID 0009-0008-1711-3155
Albert JangDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
Bashar AbuqayasDivision of Oncology, Holden Comprehensive Cancer Center, Iowa City, IA 52242, United States.
Arnab BasuDivision of Hematology-Oncology, University of Alabama O'Neal Comprehensive Cancer Center, Birmingham, AL 35233, United States.
David J BenjaminHoag Family Cancer Institute, Newport Beach, CA 92663, United States.
Vineel BhatlapenumarthiDivision of Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
Mehmet Asim BilenGenitourinary Medical Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States.
Dhvani BuchDepartment of Solid Tumor Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte 28204, United States.
Mark ChangDepartment of Solid Tumor Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte 28204, United States.
Erica ChinDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.
Sourat DarabiHoag Family Cancer Institute, Newport Beach, CA 92663, United States.
Nagendra DhanikondaDepartment of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
Pooja GhataliaDepartment of Hematology-Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, United States.
Claud M GriggDepartment of Solid Tumor Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte 28204, United States.
Abby L GrierDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
Tanya JindalDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
Joannah JungDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.
Deepak KilariDivision of Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
Hamsa L S KumarDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.
Suzanna LeeDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.
Brittany NeelandsDepartment of Solid Tumor Oncology, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Charlotte 28204, United States.
Chinmayi PandyaDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.
Jeff PawalekDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.
Jaimee StaggersDivision of Hematology-Oncology, University of Alabama O'Neal Comprehensive Cancer Center, Birmingham, AL 35233, United States.
Ahmet YildirimGenitourinary Medical Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States.
Yousef ZakhariaDivision of Oncology, Holden Comprehensive Cancer Center, Iowa City, IA 52242, United States.
Kevin K ZarrabiDepartment of Medical Oncology, Thomas Jefferson Sidney Kimmel Cancer Center, Philadelphia, PA 19107, United States.
Michael ZimmermanDepartment of Medical Oncology, Thomas Jefferson Sidney Kimmel Cancer Center, Philadelphia, PA 19107, United States.
George SledgeCaris Life Sciences, Irving, TX 75039, United States.
David SpetzlerCaris Life Sciences, Irving, TX 75039, United States.
Andrew ElliottCaris Life Sciences, Irving, TX 75039, United States.ORCID 0000-0001-8494-8031
Rana R McKayDivision of Hematology-Oncology, University of California San Diego Moores Cancer Center, La Jolla, CA 92307, United States.ORCID 0000-0002-0581-7963
Pedro C BarataDivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, United States.ORCID 0000-0002-8890-2951

Funding

Exelixis and Kure It Research
6 · The paper itself

Abstract

The REnal cancer consortium for Focused Investigation of Novel biomarkers and Expression (REFINE) consortium represents an important initiative in integrating clinical data with molecular sequencing in patients with advanced renal cell carcinoma (RCC) treated with immunotherapy-based approaches. By leveraging real-world evidence and genomic analysis, this consortium aims to explore putative predictive biomarkers with the potential to inform personalized treatment strategies. Findings from the REFINE database may further contribute to our understanding of disease courses of immunotherapy-based approaches for various molecular subtypes of RCC, associations of race and ethnicity with RCC treatment and outcomes with representation of patient populations underrepresented in clinical trials, and optimizing treatment sequencing.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellImmunotherapyKidney NeoplasmsDatabases, FactualGenomicsHumansBiomarkers, Tumorbiomarkersimmunotherapymolecular sequencingrenal cell carcinoma

Identifiers

PMID40536267
PMCPMC12204391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.